SCHEMBL3572136

SCHEMBL3572136

CC(=O)Nc1ccc(C(=O)c2ccc3c(c2)NC(=O)/C3=C/Nc2ccc(N3CCN(C)CC3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.52
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
NTRK1 P04629 2/20 0.43
NTRK3 Q16288 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
GFER P55789 1/20 0.42
NPC1 O15118 8/20 0.42
RAB9A P51151 8/20 0.42
JAK3 P52333 1/20 0.42
FLT3 P36888 1/20 0.42
NTRK2 Q16620 1/20 0.41
TP53 P04637 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3572137 1.00 CSF1R (0.52) CSF1RMEN1MAPTKMT2AKDM4E
SCHEMBL3573380 0.93 CSF1R (0.49) CSF1RMEN1MAPTKMT2AKDM4E
SCHEMBL3573384 0.93 CSF1R (0.49) CSF1RMEN1MAPTKMT2AKDM4E
SCHEMBL3582824 0.93 JAK3 (0.50) CSF1RMEN1MAPTKMT2AKDM4E
SCHEMBL3582827 0.93 JAK3 (0.50) CSF1RMEN1MAPTKMT2AKDM4E
SCHEMBL3573782 0.91 CSF1R (0.51) CSF1RMEN1MAPTKMT2AKDM4E
SCHEMBL3573781 0.91 CSF1R (0.51) CSF1RMEN1MAPTKMT2AKDM4E
SCHEMBL3569691 0.91 CSF1R (0.49) CSF1RNTRK1NTRK3NPC1RAB9A
SCHEMBL3569694 0.90 CSF1R (0.49) CSF1RMAPTKMT2AKDM4EALDH1A1
SCHEMBL3583076 0.87 CSF1R (0.47) CSF1RMAPTKMT2ANTRK1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
US-7749530-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-07-06 US disclosed
WO-2010075197-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2010-07-01 WO disclosed
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US disclosed
US-20090208557-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-20 US disclosed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP disclosed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US disclosed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208557-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 CSF1R 776/4885MEN1 3831/4885MAPT 1650/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 CSF1R 877/4885MEN1 2293/4885MAPT 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.